ProfoundBio is a US-based biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer.
Location: China, Jiangsu, Suzhou
Employees: 51-200
Total raised: $112M
Investors 3
| Date | Name | Website |
| - | LAV | lavfund.co... |
| 15.02.2024 | Octagon Ca... | octagoninv... |
| 10.03.2023 | B Capital ... | bcapgroup.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.02.2024 | Series B | $112M | - |
Mentions in press and media 19
| Date | Title | Description |
| 07.05.2026 | LTZ Therapeutics: $38 Million Financing Raised To Advance Myeloid Engager Immunotherapy Pipeline | LTZ Therapeutics announced the completion of an oversubscribed $38 million financing round to accelerate development of its Universal Myeloid Cell Engager immunotherapy platform and pipeline. The financing round was led by GL Ventures with ... |
| 14.11.2025 | Medicxi Closes €500 Million Fund To Advance Asset-Centric Biotech Innovation | Medicxi announced the close of its €500 million Medicxi V vehicle, reinforcing the firm’s position as a major European life sciences investor and adding significant capital to expand its long-standing asset-centric company creation strategy... |
| 09.10.2025 | Expedition Therapeutics: $165 Million Series A Raised For Advancing DPP1 Inhibitor For COPD | Expedition Therapeutics, a biotechnology company dedicated to developing therapies for novel inflammatory and respiratory diseases, has closed an oversubscribed and upsized Series A financing round, raising $165 million. This financing roun... |
| 29.09.2025 | Датская Genmab покупает нидерландскую фармкомпанию Merus за $8 млрд | Genmab выкупит акции Merus по цене $97 за штуку наличными, говорится в совместном заявлении компаний в понедельник. Это примерно на 41% выше цены закрытия акций Merus, котирующихся в США, по состоянию на 26 сентября. Ранее Bloomberg News со... |
| 24.10.2024 | Jade Biosciences Extends Financing; Total To $95M | Jade Biosciences, a Vancouver, BC, Canada-based biotechnology company dedicated to developing therapies for patients living with autoimmune diseases, extended its financing, bringing the total raised to $95M. The round added Frazier Life Sc... |
| 13.02.2024 | ProfoundBio Raises $112M in Series B Funding | ProfoundBio, a Seattle, WA-based clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer, raised $112M in Series B funding. The round was led by Ally Bridge Group, with parti... |
| 05.10.2023 | ProfoundBio to Participate in the Bank of America 2023 Healthcare Trailblazers Private Company Conference | SEATTLE, Oct. 5, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one mee... |
| 28.09.2023 | ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023 | SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC p... |
| 28.08.2023 | ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference | SEATTLE, Aug. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one me... |
| 26.05.2023 | ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic | PRO1160 first patient dosed in the US China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023... |
Show more